Medicare Enrolled

Dr. Dale Kooistra, M.D., PHD.

Dermatology · Poway, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
15525 POMERADO RD, Poway, CA 92064
8586758001
In practice since 2005 (20 years)
NPI: 1831182971 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kooistra from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kooistra? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kooistra

Dr. Dale Kooistra is a dermatology specialist in Poway, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kooistra performed 1,984 Medicare services across 964 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kooistra received a total of $3,914 from 30 pharmaceutical and/or device companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in dermatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kooistra is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ 1,984 Medicare services $3,914 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,984
Medicare services
Bottom 45% in CA for dermatology
964
Unique beneficiaries
$47
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~99 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Destruction of precancerous skin growths, 2-14
This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer.
870 $6 $12
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
295 $64 $159
Destruction of precancerous skin growth, 1
Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer.
244 $46 $142
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
175 $91 $232
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
65 $1 $5
Destruction of 15 or more precancerous skin growths
This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer.
64 $144 $330
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
61 $43 $99
Destruction of skin growths (warts/lesions), 1-14
This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface.
55 $91 $244
Skin biopsy, tangential
A procedure to remove a sample of the first identified skin growth for laboratory examination.
47 $86 $217
Skin growth removal and lab exam, 1-5 blocks
This procedure involves the removal of a growth from the head, neck, hands, feet, or genitals. The removed tissue is then examined under a microscope in the laboratory.
23 $510 $1,449
Injection into skin growths, 1-7
A procedure involving the injection of medication into one to seven skin growths.
21 $36 $118
Fluorouracil injection, 500 mg
Administration of a 500 mg dose of fluorouracil medication via injection.
18 $2 $5
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
17 $89 $230
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks 16 $368 $864
Destruction of cancerous skin growth on face, 0.6-1.0 cm
This procedure involves the removal or destruction of a cancerous skin lesion located on the face, ears, eyelids, nose, lips, or mouth. The lesion treated measures between 0.6 and 1.0 centimeters in diameter.
13 $147 $387
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$3,914
Total received (2018-2024)
Avg $559/year across 7 years
Top 33% in CA for dermatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
30
Companies
156
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,770 (96.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$145 (3.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,022
2023
$833
2022
$95
2021
$295
2020
$222
2019
$596
2018
$852

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$323
Janssen Biotech, Inc.
$253
Regeneron Healthcare Solutions, Inc.
$100
Novartis Pharmaceuticals Corporation
$93
PFIZER INC.
$74
Incyte Corporation
$29
Boehringer Ingelheim Pharmaceuticals, Inc.
$28
LEO Pharma Inc.
$26
UCB, Inc.
$25
REVANCE THERAPEUTICS, INC.
$21
Tempus AI, Inc
$18
Biofrontera Inc.
$17
ABBVIE INC.
$14
Top 3 companies account for 66.2% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Healthcare Solutions, Inc.
$630
E.R. Squibb & Sons, L.L.C.
$520
Janssen Biotech, Inc.
$505
PFIZER INC.
$347
GENZYME CORPORATION
$303
LEO Pharma Inc.
$195
Novartis Pharmaceuticals Corporation
$150
AbbVie, Inc.
$125
Incyte Corporation
$125
Janssen Scientific Affairs, LLC
$125
SANOFI-AVENTIS U.S. LLC
$118
Sun Pharmaceutical Industries Inc.
$118
Ortho Dermatologics, a division of Bausch Health US, LLC
$108
DERMIRA, INC.
$75
ABBVIE INC.
$62
SUN PHARMACEUTICAL INDUSTRIES INC.
$61
Boehringer Ingelheim Pharmaceuticals, Inc.
$61
AbbVie Inc.
$42
Merck Sharp & Dohme Corporation
$35
Amgen Inc.
$26
UCB, Inc.
$25
Aclaris Therapeutics, Inc.
$22
Biofrontera Inc.
$22
REVANCE THERAPEUTICS, INC.
$21
Tempus AI, Inc
$18
TARO PHARMACEUTICALS USA, INC.
$18
Arcutis Biotherapeutics, Inc.
$16
Galderma Laboratories, L.P.
$15
Taro Pharmaceuticals USA, Inc.
$15
PruGen, Inc. Pharmaceuticals
$10
Top 3 companies account for 42.3% of all-time payments
Associated products mentioned in payments ›
ABSORICA LD · ADBRY · AKLIEF · AMELUZ · Absorica LD · Ameluz · Bimzelx · CIBINQO · COSENTYX · CYLTEZO · DAXXIFY · DISEASE STATE · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ENSTILAR · EUCRISA · Enbrel · HALOG OINTMENT (Halcinonide Ointment · Humira · ILUMYA · LIBTAYO · Merlin Test · OPZELURA · QBREXZA · REMICADE · RHOFADE · RINVOQ · SILIQ · SIVEXTRO · SKYRIZI · SPEVIGO · Sotyktu · TREMFYA · Tremfya · ULTRAVATE · USP) 0.1% · Winlevi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a dermatology specialist in Poway?
Compare dermatologists in the Poway area by procedure volume, costs, and industry payment transparency.
Browse dermatologists nearby

Geographic Context

Dermatologists within 10 mi
252
Per 100K population
7.7
County median income
$102,285
Nearest hospital
PALOMAR MEDICAL CENTER POWAY
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Kooistra is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Kooistra experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Kooistra performed 870 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kooistra receive payments from pharmaceutical companies?
Yes. Dr. Kooistra received a total of $3,914 from 30 companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kooistra's costs compare to other dermatologists in Poway?
Dr. Kooistra's average Medicare payment per service is $47. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kooistra) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →